How (PEN) Movements Inform Risk Allocation Models
This article analyzes Penumbra Inc. (NYSE: PEN) using AI models to suggest trading strategies based on different risk profiles and time horizons. It highlights divergent sentiment across various horizons, indicating choppy conditions, and provides specific entry, target, and stop-loss levels for position, momentum, and risk-hedging strategies. The analysis offers institutional-grade signals for short-term, mid-term, and long-term outlooks.
Penumbra, Inc. (PEN) Stock Analysis: Unveiling a 17.8% Revenue Growth in the Dynamic Medical Devices Sector
Penumbra, Inc. (PEN), a medical devices company, has shown robust revenue growth of 17.80%, highlighting its strong expansion trajectory. Despite an elevated forward P/E ratio, analysts maintain cautiously optimistic ratings, indicating investor confidence in the company's future potential rather than current earnings. Penumbra's diverse product portfolio and reinvestment strategy for growth make it an intriguing opportunity in healthcare technology.
Candriam S.C.A. Trims Stake in Penumbra, Inc. $PEN
Candriam S.C.A. significantly reduced its stake in Penumbra, Inc. (NYSE:PEN) by 48.8% in Q3, selling 6,419 shares and retaining 6,729 shares valued at $1.705 million. This divestment occurred amidst other institutional investors adjusting their positions and notable insider selling activity, with Penumbra directors selling over $10 million in shares in the past three months. The stock currently holds a consensus "Hold" rating from analysts, with an average price target of $358.
PEN Stock Price, Forecast & Analysis | PENUMBRA INC (NYSE:PEN)
This article provides a detailed analysis of Penumbra Inc. (NYSE: PEN) stock, covering its price performance, technical and fundamental ratings, financial highlights, and analyst forecasts. The company, which specializes in medical devices for thrombectomy, has a current stock price of $339.3 USD and analysts forecast a 7.34% price increase in the next year. It also details the company's profile, including its products, market, and key financial statistics.
The Truth About Penumbra Inc: Why Wall Street Is Watching While TikTok Sleeps On It
Penumbra Inc. (PEN) is a medical technology company specializing in minimally invasive devices for stroke and vascular issues, attracting Wall Street attention despite low social media buzz. The article highlights Penumbra's critical role in healthcare, operating in a highly regulated market with significant barriers to entry, making it a compelling long-term investment for those focused on medical innovation rather than viral trends. Investors are advised to research the company's financials, product pipelines, and regulatory landscape, rather than relying on short-term market hype.
Wesbanco Bank Inc. Purchases New Position in Penumbra, Inc. $PEN
Wesbanco Bank Inc. recently acquired 7,502 shares of Penumbra, Inc. (NYSE: PEN) valued at approximately $1.9 million during the third quarter. While analysts' sentiment is mixed, with an average "Hold" rating and a $358 target price, JPMorgan upgraded the stock to "Overweight" with a $370 target. Institutional investors collectively hold nearly 89% of the company’s stock.
Penumbra (PEN) Projected to Post Earnings on Tuesday
Penumbra (NYSE:PEN) is expected to announce its Q4 2025 earnings before the market opens on Tuesday, February 17th, with analysts forecasting earnings of $1.12 per share. The company's stock shows a market cap of $13.29 billion and a P/E ratio of 81.18. Recent insider selling has been noted, while institutional investors own a significant portion of the stock.
Penumbra Sale To Boston Scientific Recasts Growth Story For Investors
Penumbra (NYSE:PEN) is being acquired by Boston Scientific in a US$14.5 billion deal, transforming its growth narrative from an independent device maker to a unit within a larger medical technology platform. This acquisition follows strong quarterly results from Penumbra, including significant revenue growth, and represents a major consolidation in the medical device sector. The deal's completion depends on regulatory and shareholder approvals, with investors now focusing on Boston Scientific's integration plans and the long-term implications for Penumbra's specialized therapies.
Penumbra, Inc. $PEN Stock Holdings Lowered by Principal Financial Group Inc.
Principal Financial Group Inc. reduced its stake in Penumbra (NYSE:PEN) by 20.8% in the third quarter, selling 26,485 shares and retaining 100,973 shares valued at $25.6 million. Despite this, other institutional investors increased their holdings, and Penumbra exceeded quarterly earnings and revenue estimates. The company currently has a consensus "Hold" rating from analysts with an average target price of $358.00.
Penumbra (PEN) Reported Revenue Growth of 16.9% in Q4
Baron Health Care Fund highlighted Penumbra, Inc. (NYSE: PEN) in its Q4 2025 investor letter, noting the medical device manufacturer's strong 16.9% constant currency revenue growth and 18.5% U.S. Thrombectomy revenue growth. The company's stock has seen significant performance, including a 31.20% increase over the past twelve months, and an announcement in early January of its acquisition by Boston Scientific for $14.5 billion. While Penumbra is not among the 30 most popular stocks for hedge funds, its solid financial results contributed to the fund's outperformance in the healthcare equipment sector.
AGF Management Ltd. Makes New $3.14 Million Investment in Penumbra, Inc. $PEN
AGF Management Ltd. has made a new investment of $3.14 million in Penumbra, Inc. (NYSE:PEN) by acquiring 12,412 shares in the third quarter. While institutional investors largely hold the stock, analysts have mixed ratings, with a consensus "Hold" and an average target price of $358. Insider selling has also been noted, with 33,772 shares sold over the last three months.
Penumbra (PEN) Reported Revenue Growth of 16.9% in Q4
Baron Health Care Fund's Q4 2025 investor letter highlighted medical device manufacturer Penumbra, Inc. (NYSE: PEN) for its strong financial results, including 16.9% constant currency revenue growth. The company also announced an agreement to be acquired by Boston Scientific Corporation for approximately $14.5 billion. Despite this, the fund considers certain AI stocks to have greater upside potential.
Hantz Financial Services Inc. Lowers Position in Penumbra, Inc. $PEN
Hantz Financial Services Inc. reduced its stake in Penumbra, Inc. by 17.1% during the third quarter, now owning 37,110 shares valued at approximately $9.4 million. Penumbra beat Q3 earnings expectations with an EPS of $0.97 and revenue of $354.69 million, exceeding analyst estimates. Despite the positive earnings, multiple insider selling activities have been reported, with directors selling over $10 million worth of shares in the last three months.
Thrivent Financial for Lutherans Purchases 44,185 Shares of Penumbra, Inc. $PEN
Thrivent Financial for Lutherans increased its stake in Penumbra, Inc. (NYSE:PEN) by 13.7% in the third quarter, acquiring an additional 44,185 shares to bring its total holdings to 367,062 shares valued at approximately $92.98 million. Despite corporate insiders selling over $10 million worth of stock and analyst sentiment shifting to a "Hold" rating, Penumbra recently beat quarterly EPS estimates and reported a 17.8% year-over-year revenue increase. The company's stock currently has a consensus "Hold" rating with an average target price of $358.00.
Penumbra, Inc. (NYSE:PEN) Receives Consensus Recommendation of "Hold" from Brokerages
Eighteen brokerages have given Penumbra, Inc. (NYSE:PEN) a consensus "Hold" rating, with an average 12-month price target of $358. While the company recently exceeded quarterly earnings and revenue estimates, its stock is considered richly valued with a PE ratio of 85.71 and trading near its 12-month high. Recent insider selling and several downgrades from major firms like Citigroup and UBS suggest a cautious outlook despite strong institutional ownership.
Penumbra, Inc. $PEN Shares Acquired by New York State Common Retirement Fund
The New York State Common Retirement Fund increased its holdings in Penumbra, Inc. (NYSE:PEN) by 8.7% in Q3, now owning 82,849 shares valued at $20,987,000. Penumbra exceeded Q3 earnings expectations, reporting $0.97 EPS against an estimated $0.90, with revenue up 17.8% year-over-year. Despite recent insider selling and analyst downgrades leading to a consensus "Hold" rating, the company's stock shows strong year-to-date performance.
Penumbra Acquisition Finalized in Multi-Billion Dollar Deal with Boston Scientific
Boston Scientific has finalized its acquisition of Penumbra, Inc. in a strategic deal valued at approximately $14.5 billion, aiming to expand its neurovascular and cardiovascular device portfolio. The acquisition, which involves Boston Scientific paying $374 per share, is expected to enhance its competitive standing in a high-growth market segment. Penumbra recently reported strong preliminary financial results for Q4 2025 and launched its innovative Lightning Flash 3.0 system, a new computer-assisted vacuum thrombectomy device.
Penumbra Launches Lightning Flash 3.0 — The Next Evolution in CAVT Technology
Penumbra has launched Lightning Flash 3.0, an advanced Computer Assisted Vacuum Thrombectomy (CAVT) system designed for enhanced clot detection and rapid removal of pulmonary and venous thrombus. This new system boasts 1.3x faster clot removal and 60% fluid savings compared to its predecessor, building on the success of the STORM-PE trial which demonstrated the superiority of CAVT technology in reducing right heart strain for acute intermediate-high risk pulmonary embolism. Lightning Flash 3.0 is intended to improve physician experience and patient outcomes by offering a more efficient and safer thrombectomy solution.
Y Intercept Hong Kong Ltd Cuts Position in Penumbra, Inc. $PEN
Y Intercept Hong Kong Ltd significantly reduced its stake in Penumbra, Inc. (NYSE:PEN) by 74.1% in Q3, selling 16,161 shares and retaining 5,659 shares. Despite this reduction, other large institutional investors like Invesco Ltd., Norges Bank, Man Group plc, and AQR Capital Management LLC increased their positions, leading to an overall institutional ownership of 88.88%. Wall Street analysts maintain a "Hold" rating with an average target price of $358.00, and Penumbra recently reported strong Q earnings, beating consensus estimates with 17.8% year-over-year revenue growth.
Boston Scientific Buyout Caps Penumbra Upside And Shifts Investor Focus
Boston Scientific has agreed to acquire Penumbra (NYSE:PEN) for $14.8 billion in cash and stock, valuing Penumbra at $374 per share. This deal will lead to Penumbra's delisting from the NYSE and shifts investor focus from its prior high-growth narrative to the terms and completion of the acquisition. Investors now face a decision between cash proceeds or continued exposure through Boston Scientific shares, with the transaction subject to regulatory approvals and shareholder vote.
Halper Sadeh LLC Investigates Penumbra and RAPT Transactions
Halper Sadeh LLC is investigating the proposed acquisition of Penumbra, Inc. by Boston Scientific Corporation, scrutinizing the terms of the deal which offer Penumbra shareholders either Boston Scientific common stock or cash. The firm is also examining GSK plc's acquisition of RAPT Therapeutics, Inc. for $58.00 per share. The investigations aim to ensure that Penumbra and RAPT shareholders' fiduciary duties are met and their legal rights are protected during these transactions.
Hussman Strategic Advisors Inc. Makes New Investment in Penumbra, Inc. $PEN
Hussman Strategic Advisors Inc. recently opened a new position in Penumbra, Inc. (NYSE:PEN), purchasing 12,600 shares valued at approximately $3.19 million, making it their 23rd largest holding. Despite significant insider selling totaling over $10 million in the past 90 days, institutional investors hold a substantial 88.88% of the stock. Wall Street analysts currently rate Penumbra as a "Hold" with an average target price of $358, while the company trades near its 1-year high and has a P/E ratio of 85.9.
Strs Ohio Cuts Stock Holdings in Penumbra, Inc. $PEN
Strs Ohio significantly reduced its stake in Penumbra, Inc. (NYSE:PEN) by 33.7% in the third quarter, selling 11,098 shares and retaining 21,794 shares valued at $5.52 million. This reduction comes amid varied analyst sentiment, with a consensus "Hold" rating, though Bank of America recently raised its price objective. The company has seen insider selling totaling over $10 million in the past quarter, despite Penumbra beating its recent quarterly EPS and revenue estimates and trading near its 52-week high.
EFG Asset Management North America Corp. Acquires 3,631 Shares of Penumbra, Inc. $PEN
EFG Asset Management North America Corp. increased its stake in Penumbra, Inc. by 21.9% in the third quarter, acquiring an additional 3,631 shares, bringing its total to 20,192 shares valued at approximately $5.12 million. Penumbra reported strong third-quarter earnings, beating analyst expectations with 17.8% year-over-year revenue growth. Despite this, analysts have a consensus "Hold" rating on the stock, with recent insider selling of about 34,144 shares.
Penumbra launches next-gen Lightning Flash 3.0 thrombectomy system
Penumbra has launched its new Lightning Flash 3.0 computer-assisted vacuum thrombectomy (CAVT) system, featuring significant upgrades for treating pulmonary and venous thrombus. This latest version boasts faster clot removal, increased fluid savings, and improved clot detection capabilities. The launch follows positive results from the STORM-PE study, which showed the system's effectiveness in reducing right heart strain in patients with acute intermediate high-risk pulmonary embolism.
Boston Scientific Penumbra Deal Recasts Growth Prospects In Thrombectomy And Neurovascular
Boston Scientific has agreed to acquire Penumbra (NYSE:PEN) for approximately $14.8 billion in a cash and stock transaction. This deal is expected to significantly reshape the thrombectomy and neurovascular therapies market by integrating Penumbra's portfolio with Boston Scientific's extensive scale. The acquisition offers Penumbra shareholders a clear liquidity event at $374 per share and addresses previous concerns about Penumbra's size and capital allocation capabilities.
Baillie Gifford & Co. Sells 13,581 Shares of Penumbra, Inc. $PEN
Baillie Gifford & Co. reduced its stake in Penumbra, Inc. by 1.5% in the third quarter, selling 13,581 shares and now holding 908,546 shares valued at $230.15 million. Analyst sentiment for Penumbra is mixed with a "Hold" consensus rating and a $358 price target. The company reported strong Q3 earnings, beating analyst estimates for both EPS and revenue, but insiders have sold a significant amount of shares recently.
Boston Scientific announces agreement to acquire Penumbra, Inc.
Boston Scientific (NYSE: BSX) will acquire Penumbra, Inc. (NYSE: PEN) in a cash and stock transaction valued at approximately $14.5 billion, or $374 per share. This acquisition aims to expand Boston Scientific's cardiovascular portfolio, particularly in mechanical thrombectomy and neurovascular segments, addressing the increasing prevalence of vascular diseases globally. Penumbra's CEO, Adam Elsesser, will join Boston Scientific's board, and the transaction is expected to close in 2026.
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—PEN, DBRG, FFIC, and FOLD
Monteverde & Associates PC, a class action firm, is investigating several mergers impacting shareholders of Penumbra, DigitalBridge Group, Flushing Financial Corp., and Amicus Therapeutics. The firm is offering free consultations to shareholders concerned about the terms of these proposed transactions, which involve stock or cash considerations. Monteverde & Associates PC has a track record of recovering money for shareholders and invites those affected to contact them for more information.
Penumbra Inc stock hits all-time high at 352.3 USD By Investing.com
Penumbra Inc. stock reached an all-time high of $352.3, driven by a 33.03% gain over the past year and 52.26% over the last six months. Despite being considered overvalued with its RSI in overbought territory, the company maintains a "GREAT" financial health score. Recent news includes strong preliminary Q4 2025 revenue figures and an acquisition announcement by Boston Scientific for $374 per share, leading several analysts to downgrade Penumbra to "Hold" or "Neutral" with a target price matching the acquisition offer.
Halper Sadeh Investigates Penumbra and Others for Potential Violations
Halper Sadeh LLC is investigating several companies, including Penumbra, FONAR Corporation, and Green Dot Corporation, for potential violations of fiduciary duties to shareholders in their recent transactions. The firm is offering free legal consultations to shareholders concerned about their rights and seeking increased compensation. The investigations aim to ensure investor interests are protected in these sales and acquisitions.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of
Brodsky & Smith LLC is notifying investors of investigations into several companies—RAPT Therapeutics, Penumbra, Calavo Growers, and FONAR Corporation—regarding their respective merger agreements. The firm is investigating whether the boards of these companies breached their fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders in the acquisition deals. Shareholders are encouraged to contact Brodsky & Smith for discussions regarding these investigations.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)
Brodsky & Smith announced investigations into potential breaches of fiduciary duties by the boards of RAPT Therapeutics, Penumbra, Calavo Growers, and FONAR Corporation. These investigations concern whether the merger agreements for these companies provide fair value to shareholders and involved fair processes. Investors are invited to contact the firm for more information regarding these investigations.
Penumbra Inc stock hits all-time high at 352.3 USD
Penumbra Inc. (PEN) stock reached an all-time high of $352.30, driven by robust performance and investor confidence. The medical device company's stock has seen significant gains over the past six months and year, though InvestingPro data suggests it may be overvalued. Recent announcements include strong preliminary Q4 and full-year 2025 revenues, alongside an acquisition by Boston Scientific for $374 per share, leading several analysts to downgrade the stock to a 'Hold' or 'Neutral' rating with a target price matching the acquisition offer.
Penumbra (PEN) Sees Downgrade with Revised Price Target from Canaccord Genuity
Canaccord Genuity has downgraded Penumbra (PEN) from Buy to Hold, while simultaneously raising its price target from $359.00 to $374.00. This follows several other recent downgrades from various brokerage firms, despite consistent upward revisions in price targets. Penumbra, which designs and manufactures medical devices for thrombectomy and embolization, now has an average analyst target price of $350.16, indicating a slight downside from its current trading price, though GuruFocus estimates a fair value of $357.00.
[425] Penumbra Inc Business Combination Communication | PEN SEC Filing - Form 425
Boston Scientific Corporation announced its definitive agreement to acquire Penumbra, Inc., a leading innovator in mechanical thrombectomy and neurovascular therapies. This acquisition will allow Boston Scientific to enter new, fast-growing segments within the vascular space, expanding access to novel technologies for patients globally. The communication was made via Boston Scientific's LinkedIn account on January 15, 2026.
Boston Scientific to acquire Penumbra (NYSE: PEN) in $14.5B deal
Boston Scientific has announced a definitive agreement to acquire Penumbra, Inc. for $14.5 billion in a cash-and-stock transaction. This acquisition aims to expand Boston Scientific's cardiovascular portfolio and re-establish a strong neurovascular business, integrating Penumbra's devices for treating stroke-causing blood clots and pulmonary embolism. The deal is expected to close this year, with projected slight profit dilution for Boston Scientific in the first year, becoming neutral to beneficial thereafter.
Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc. - PEN
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Penumbra, Inc. (NYSE: PEN) to Boston Scientific Corporation (NYSE: BSX) for $374.00 in cash or 3.8721 shares of Boston Scientific stock. KSF is seeking to determine if the consideration and sale process are adequate or if the offer undervalues Penumbra. Shareholders who believe the transaction undervalues the company are encouraged to contact KSF.
PEN Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Penumbra, Inc. is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the proposed sale of Penumbra, Inc. (NYSE: PEN) to Boston Scientific Corporation. The firm is examining whether the $374.00 cash or 3.8721 shares of Boston Scientific common stock offer is fair to Penumbra shareholders. The investigation seeks to determine if Penumbra's board failed to secure the best possible consideration or adequately disclose material information regarding the merger.
Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results
Penumbra, Inc. announced preliminary unaudited financial results for Q4 and full year 2025, showing significant revenue growth. Fourth-quarter revenue is estimated between $383.0 million and $384.8 million, a 21.4% to 22.0% increase over Q4 2024, with full-year revenue projected to be $1,401.3 million to $1,403.1 million, an increase of 17.3% to 17.5% over full year 2024. The company also reported strong gross margins and income from operations for both periods.
Shareholder Alert: The Ademi Firm investigates whether Penumbra, Inc. is obtaining a Fair Price for its Public Shareholders
Ademi LLP is investigating Penumbra (NYSE: PEN) regarding its recently announced transaction with Boston Scientific, examining potential breaches of fiduciary duty by Penumbra's board. The firm is concerned about whether public shareholders are receiving a fair price, given the transaction structure which offers $374 in cash or 3.8721 shares of Boston Scientific stock, with insiders reportedly receiving substantial benefits. Ademi LLP questions the restrictive nature of the agreement, which imposes a significant penalty if Penumbra accepts a competing bid.
Penumbra Announces Strong Preliminary Revenue Growth for 2025
Penumbra (PEN) announced strong preliminary revenue growth for 2025, with Q4 revenue up 21-22% year-on-year and full-year revenue up 17-18%. This performance precedes its acquisition by Boston Scientific, valued at $374 per share in cash or 3.8721 Boston Scientific shares. TipRanks’ AI Analyst, Spark, rates PEN as "Outperform" due to its financial strength, though notes potential overvaluation and overbought technical indicators.
Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results
Penumbra, Inc. has released preliminary unaudited financial results for the fourth quarter and full year 2025, showing significant revenue growth. The company reported fourth-quarter revenue between $383.0 million and $384.8 million, an increase of 21.4% to 22.0% year-over-year, and full-year revenue of $1,401.3 million to $1,403.1 million, representing 17.3% to 17.5% growth compared to 2024. These results highlight strong operational performance, with income from operations ranging from $56.9 million to $60.4 million for Q4 2025 and $186.9 million to $190.4 million for the full year.
Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results
Penumbra, Inc. announced preliminary unaudited financial results for the fourth quarter and full year 2025, showing strong revenue growth. Fourth-quarter revenue is projected between $383.0 million and $384.8 million, representing over 21% growth, while full-year revenue is expected to be $1401.3 million to $1403.1 million, an increase of over 17%. The company also reported solid gross margins and income from operations for both periods.
Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results
Penumbra, Inc. announced its preliminary unaudited financial results for the fourth quarter and full year 2025. The company reported robust revenue growth, with fourth-quarter revenues between $383.0 million and $384.8 million, and full-year revenues ranging from $1,401.3 million to $1,403.1 million. These figures represent significant growth compared to 2024, highlighting strong operational performance.
Penumbra (PEN) Gains Amid Takeover Speculation
Penumbra (PEN) shares rose 3.8% due to takeover speculation, with a Betaville alert suggesting an unknown buyer. The medical device company increased its 2025 revenue forecast and demonstrates strong financial health with robust margins and growth metrics, although insider selling has been noted. Its valuation metrics are near historical highs, reflecting strong investor confidence and positive analyst sentiment.
Penumbra (NYSE:PEN) Stock Price Down 8.1% - What's Next?
Penumbra Inc. (NYSE: PEN) saw its stock price drop 8.1% to $293.47 today on lower-than-average trading volume. Despite this decline and recent insider selling, analysts maintain a "Moderate Buy" consensus rating with an average target price of $340.40, following strong Q3 earnings that beat estimates. The company manufactures medical devices for neurovascular and peripheral vascular conditions.
Penumbra (PEN) stock slides 5% after CEO flags manufacturing shift at JPM conference
Penumbra (PEN) shares dropped over 5% after CEO Adam Elsesser announced at the J.P. Morgan Healthcare Conference that the company would shift its manufacturing base away from California. This news caused investor uncertainty regarding future costs, capacity, and potential supply disruptions, despite the company's strong valuation and analyst consensus. The move could either boost future margins or incur significant transition expenses, with the next clear catalyst being the upcoming earnings report.
CE Mark Granted to Penumbra’s MIDWAY and ACCESS25 Delivery Catheters
Penumbra Inc. has received CE Mark approval for its MIDWAY and ACCESS25 delivery catheters, enhancing its neuro access platform. These catheters are designed to provide excellent trackability and platform stability for delivering various embolization therapies in the neurovasculature, including microcatheters, embolization coils, and flow diverters. The ACCESS25 specifically supports the delivery of Penumbra's 0.020-inch coil platform for neurovascular embolization, expanding treatment options for challenging medical conditions.
Penumbra stock hits 52-week high at $321.47
Penumbra Inc. (PEN) stock reached a new 52-week high of $321.47, reflecting a significant 27.24% increase over the past year and investor confidence. Despite a P/E ratio of 77.13 suggesting potential overvaluation, analysts maintain a "Strong Buy" consensus with a 9% upside potential, driven by strong quarterly results, raised revenue guidance, and promising product launches.
